Responses
Abstracts Accepted for Publication
Rheumatoid arthritis - other biologic treatment
AB0395 Subcutaneous tocilizumab as monotherapy or in combination with a csdmard in patients with rheumatoid arthritis: 24 weeks results of the french phase iiib study, “tosca”
Compose a Response to This Article
Other responses
No responses have been published for this article.